SAB Biotherapeutics, Inc.
SABS
$3.94
-$0.21-5.06%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.27M | 18.74M | -37.06M | -34.28M | -34.11M |
| Total Depreciation and Amortization | 3.08M | 3.10M | 3.31M | 3.59M | 4.79M |
| Total Amortization of Deferred Charges | 261.10K | -- | -- | -- | -- |
| Total Other Non-Cash Items | -57.71M | -61.12M | 757.50K | -2.19M | -2.68M |
| Change in Net Operating Assets | -3.69M | 1.75M | 2.22M | 1.54M | -2.30M |
| Cash from Operations | -44.78M | -37.53M | -30.77M | -31.34M | -34.29M |
| Capital Expenditure | -933.20K | -55.40K | -155.70K | -208.20K | -337.30K |
| Sale of Property, Plant, and Equipment | 500.00 | 500.00 | 500.00 | 500.00 | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -120.77M | -110.61M | 18.20M | 24.28M | -11.63M |
| Cash from Investing | -121.71M | -110.67M | 18.05M | 24.07M | -11.96M |
| Total Debt Issued | -- | 516.00K | 516.00K | 516.00K | 516.00K |
| Total Debt Repaid | -418.40K | -655.80K | -1.27M | -1.35M | -1.42M |
| Issuance of Common Stock | 168.73M | 168.73M | 0.00 | 0.00 | 20.40K |
| Repurchase of Common Stock | -11.30K | -31.90K | -27.00K | -27.00K | -24.90K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -800.00 | 0.00 | -25.00K | -93.70K | -261.10K |
| Cash from Financing | 168.30M | 168.56M | -804.90K | -952.10K | -1.17M |
| Foreign Exchange rate Adjustments | -213.50K | -104.30K | -19.30K | -170.40K | -241.20K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.60M | 20.25M | -13.55M | -8.39M | -47.67M |